|1.||Fry, D W: 1 article (01/2000)|
|2.||Bridges, A J: 1 article (01/2000)|
|3.||Roberts, B J: 1 article (01/2000)|
|4.||Sherwood, V: 1 article (01/2000)|
|5.||Elliott, W L: 1 article (01/2000)|
|6.||Dykes, D J: 1 article (01/2000)|
|7.||Rose, S: 1 article (01/2000)|
|8.||Zhou, H: 1 article (01/2000)|
|9.||Leopold, W R: 1 article (01/2000)|
|10.||Patmore, S J: 1 article (01/2000)|
01/01/2000 - "Subcutaneous, intraperitoneal, and oral routes of administration have also shown in vivo antitumor activity of PD 0169414 in a panel of human tumor xenografts. "
01/01/2000 - "Oral administration of 260 mg/kg per day PD 0169414 for 15 days to animals bearing advanced-stage A431 epidermoid carcinoma produced a 28.2-day delay in tumor growth and resulted in three complete and three partial tumor regressions in six animals. "
01/01/2000 - "Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts."
01/01/2000 - "PD 0169414 is a specific, irreversible inhibitor of EGFr family tyrosine kinases with significant in vivo activity against a variety of relevant human tumor xenografts."
|2.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Heterologous Transplantation (Xenotransplantation)